86 results about "Ovarian tissue" patented technology

The invention relates to a mesenchymal stem cell exosome ovary injection device which comprises a puncture needle, an elastic tube and an injector, a plurality of liquid outlet holes are formed in the side wall of the puncture needle, the needle tip of the puncture needle is a sharp solid needle tip, one end of the elastic tube is communicated with the puncture needle through a hollow connecting part, the other end of the elastic tube is provided with a silica gel plug, and the injector is connected with the puncture needle through a connecting part. One end, far away from the elastic tube, of the silica gel plug is provided with a guide hole which is sunken inwards, and the guide hole is used for guiding a needle head of the injector to pierce the silica gel plug. The needle tip is solid, sharp and high in rigidity, and can smoothly pierce into the ovarian tissue; a plurality of liquid outlet holes are formed in the side surface of the puncture needle, so that exosomes can be more uniformly distributed in the ovary during puncture and injection, the puncture frequency is reduced, and the physical damage to the ovary of a patient is reduced; a silica gel plug is designed at one end of the elastic tube for plugging, so that liquid backflow in the process of switching different injection liquid medicine can be prevented, and the infection risk is reduced.

The invention provides an ovary-targeting ROS response type SS31 nano-particle and a preparation method and application thereof, and belongs to the field of biomedicine.The ovary-targeting ROS response type SS31 nano-particle is constructed by utilizing a porous metal organic framework to carry hyaluronic acid and utilizing an ROS response type thioketone linker to be combined with mitochondrial targeting peptide SS31, and the ovary-targeting ROS response type SS31 nano-particle is used for preparing the ovary-targeting ROS response type SS31 nano-particle. And the SS31 is targeted and delivered to the ovarian tissue. The nanoparticles target ovary and slowly release SS31 under the action of ROS, so that oxidative stress of oocytes and granular cells caused by female reproductive system diseases such as premature ovarian failure, polycystic ovarian syndrome and the like is reduced, and the mitochondrial function of the oocytes and the granular cells is improved; and a foundation is laid for the subsequent clinical treatment of diseases related to the mitochondrial dysfunction of the female reproductive system by using the SS31.

The invention discloses application of rapamycin combined with a vascular endothelial growth factor A in improvement of an ovarian tissue function. The improvement of the ovarian tissue function comprises any one or more than two of the following aspects: increasing the survival rate of follicles, prolonging the functional life of the ovarian tissue and improving the quality of oocytes. The effective concentration of the rapamycin is 500nM, and the effective concentration of the vascular endothelial growth factor A is 5ng / mL. The follicle loss dynamic after OTCT is tracked through a mouse model, it is found that rapid follicle loss is related to tip cell damage and primordial follicle activation, then a rapamycin and vascular endothelial growth factor A combination strategy is provided, follicle loss can be remarkably reduced, the reproductive function period can be prolonged, and the oocyte quality can be improved; according to the invention, a systematic solution is provided for OTCT technology optimization.

The invention belongs to the technical field of biological medicine, and particularly relates to a reagent for improving ovarian development and a preparation method and application thereof. The reagent for improving ovarian development is prepared by mixing the following raw materials in parts by weight: 20-30 parts of N-acetylcysteine; 5 to 10 parts of tranexamic acid; 3 to 8 parts of creatine; and 3000 parts of water. According to the reagent, the mRNA expression of PKD1P6 and follicle stimulating hormone receptors (FSHR) in ovarian tissues is up-regulated, the activity and functions of cumulus granular cells are enhanced, and apoptosis of the cumulus granular cells is inhibited, so that the effects of effectively promoting follicle development and inhibiting the apoptosis of the cumulus granular cells are achieved.

The invention relates to an isolated culture method of functional Chinese softshell turtle ovarian granular cells. The isolated culture method comprises the following steps: S1, collecting ovarian tissues: collecting Chinese softshell turtle ovarian tissues; s2, separating and collecting a granular cell layer; s3, digesting and collecting granular cells; s4, primary culture of granulosa cells: transferring the collected cells into a cell culture bottle containing 4 ml of a complete culture medium for primary culture, wherein the complete culture medium comprises the following main components: a DMEM culture medium, 15% of fetal calf serum, 1% of penicillin streptomycin and 1% of an insulin-transferrin-selenium additive; and S5, subculturing the granular cells. The isolated culture method and the culture medium system provided by the invention are simpler and more time-saving and labor-saving; according to the method, the aromatase CYP19A1 can be expressed normally, the characteristics of the granular cells are kept, the aromatase CYP19A1 can be expressed normally, it is indicated that the in-vitro cultured cells can keep the functionality of the cells, and the in-vitro proliferation capacity of the granular cells is improved to a great extent.

The invention discloses a composition and a method for constructing ovarian organoid based on a clinical tissue sample. The composition comprises a sample preservation solution, a sample digestive juice and a sample culture medium, the method comprises the following operation steps: transporting a preservation solution A to a laboratory, and pretreating to obtain tissue fragment precipitates; carrying out resuspension incubation on the tissue fragment precipitate by using digestive juice B for digestion; collecting tissue blocks which are not completely digested and filtered, and performing secondary digestion to obtain single cells; combining the cells obtained in two times to obtain the required single cell; adding matrigel, then adding the mixture into a pore plate, and putting the pore plate into an incubator until the matrigel is solidified; and taking out the pore plate, adding a culture medium L2, and culturing to obtain the ovarian organ constructed based on the clinical sample. According to the method, the ovarian organoid is efficiently constructed from the ovarian tissue sample; the provided culture solution formula makes up the dilemma that normal ovarian tissue organoids are difficult to form and normal tissue-derived organoids are difficult to passage at present, and reduces the burden and experiment cost brought by sampling in the disease research process.

The application discloses a doxorubicin scavenger for protecting ovarian fertility and a preparation method thereof, comprising a DNA complex wrapped by a red blood cell membrane, wherein the red blood cell membrane is surface-modified by an anti-Mullerian duct antibody alphaAMH; the doxorubicin scavenger is specifically combined with AMH which is highly expressed in ovarian tissues through alphaAMH, is enriched in the ovarian part in a targeted manner, adsorbs doxorubicin through a DNA fragment in the DNA complex, reduces toxic damage of doxorubicin to ovarian cells, and further protects ovarian fertility. The doxorubicin scavenger can adsorb injected doxorubicin Dox, reduce side effects of doxorubicin Dox on ovarian granulosa cells, and further protect ovarian function and fertility.

The invention provides an FSH33 peptide modified DNA tetrahedron nano delivery system as well as a preparation method and application thereof, and aims to provide a safe and efficient antioxidant nano drug and optimize the enrichment efficiency to promote ovarian aging and ovarian tissue damage repair. The system is a nano-scale nucleic acid compound composed of a tetrahedral DNA frame structure and an FSH targeting peptide. The tetrahedral DNA frame structure is a microscopic 3D stereoscopic tetrahedral structure formed by self-assembly of DNA single chains of a specific nucleic acid sequence, wherein each side extends out of a viscous end used for being connected with an FSH peptide. The research finds that the DNA tetrahedron can safely and effectively improve the ovarian endocrine function, ovarian reserve, fertility and the like of mice in a drug protection group, has no obvious toxic or side effect on all organs and tissues of the whole body, and can promote the repair of ovarian oxidative damage.

The invention relates to an effect of an REV-ERBalpha agonist SR9009 in the aspect of delaying ovarian senescence, and aims at the problem of fertility decline caused by cliff-type decline of ovarian functions of women over 35 years old, the SR9009 is applied to activate an REV-ERBalpha circadian rhythm signal channel in ovarian tissues, inhibit excessive autophagy of granular cells and maintain a primordial follicle dormancy state, so that the agonist SR9009 can be used for delaying ovarian senescence. Therefore, the original follicle depletion speed is delayed, follicle storage is maintained, and the ovary reproductive function cycle is prolonged. The effect is verified by a mammal model: REV-ERBalpha protein expression in an ovary of an aging individual is reduced, rhythmicity expression is disordered, autophagy of granulosa cells can be effectively inhibited in the ovary of the aging individual intervened by the SR9009, and the number of residual primordial follicles and the number of total follicles are obviously greater than those of an untreated control group. The invention provides an innovative treatment strategy of targeted rhythm regulation and control for clinical intervention of ovarian aging.

This invention relates to the field of ovarian tissue in vitro culture technology, and discloses a formulation for activating and increasing follicles and its application. The formulation consists of a PI3K / Akt / mTOR pathway activator and / or a PTEN inhibitor SF1670. The PI3K / Akt / mTOR pathway activator is a 5-15 μM statin, and the PTEN inhibitor is a 20-50 μM SF1670. Using this formulation can achieve the follicle activation and increase effect of existing technologies, contributing to the development and selection of in vitro follicle activators in clinical practice. Furthermore, the use of this formulation opens up a new technological application area for statins.

Disclosed are a method and culture medium for performing an in vivo treatment on ovaries of mammals including humans or performing in vitro culturing on ex vivo ovaries or ovarian tissue by means of using 4-vinylcyclohexene diepoxide. The method or culture medium provided facilitates the retention and enhancement of the developmental and reproductive potential of mammalian ovaries or ovarian tissue, and is particularly capable of promoting follicle maturation and increasing the number of ovulations.

The invention discloses a stem cell exosome composition for improving premature ovarian failure as well as a preparation method and application of the stem cell exosome composition. The composition is composed of human umbilical cord mesenchymal stem cell exosomes obtained through hypoxia and TGF-beta1 combined pretreatment and resveratrol, and the human umbilical cord mesenchymal stem cell exosomes and the resveratrol are compounded according to a specific mass ratio. The pre-treatment condition is that 1% oxygen concentration and 10 ng / ml TGF-beta1 are co-cultured for 48 hours, and the condition can synergistically up-regulate the expression level of specific miRNA in the exosome. The composition prepared through physical incubation and an ultrafiltration method shows a clear synergistic treatment effect in vitro and in vivo, the combination index of the composition is 0.38-0.45, ovarian endocrine indexes can be effectively recovered, follicular reserve can be protected, and oxidative stress and inflammation states of ovarian tissues can be remarkably improved. The invention provides a novel treatment strategy with a novel mechanism and a remarkable curative effect for premature ovarian failure, especially chemotherapy-induced ovarian function impairment.

The invention belongs to the technical field of medicines, and particularly relates to application of a licorice extract in preparation of a medicine for treating premature ovarian failure. On the basis of network pharmacology prediction and animal experiment verification, through experimental exploration, it is clear that diammonium glycyrrhizinate can treat premature ovarian failure by improving ovarian tissue energy metabolism, reducing the oxidative stress level and inhibiting ovarian cell apoptosis, and also can treat premature ovarian failure by improving the ovarian growth and development microenvironment. According to the present invention, the growth and development rate of ovarian granular cells and membrane cells is improved, the sufficient quantity of granular cells and membrane cells are ensured to secrete female progestational hormone, the damaged ovarian tissue is further protected, the new strategy and hope are provided for the treatment of premature ovarian failure, and the pharmaceutical composition is expected to become the safe and effective treatment drug.

The invention discloses a fish ovarian RNA (Ribonucleic Acid) extraction method which comprises the following steps: taking out ovarian tissues from living fish, and soaking the ovarian tissues into liquid nitrogen for freezing; taking out the frozen ovarian tissue, and grinding the ovarian tissue in liquid nitrogen; transferring the ground ovarian tissue into a pre-cooled tube, adding pre-cooled Trazol, oscillating, standing, centrifuging, and taking a supernatant; and purifying, precipitating and purifying in sequence to obtain the fish ovary RNA. The fish ovary RNA extracted by adopting the extraction method disclosed by the invention is not easy to degrade, meets scientific research experiment standards, and is high in extraction efficiency, simple and convenient to operate and high in universality.

The application relates to a method for establishing an early ovarian failure rat model, which comprises the following steps: taking healthy rats, and performing gavage on the rats according to a dosage of 10-20 mg / Kg of a phytostilbene preparation, wherein the dosage is the ratio of phytostilbene to the weight of the rats, and obtaining the early ovarian failure rat model after four days of administration. The early ovarian failure rat model is obtained by performing gavage on the rats after the phytostilbene preparation, the model is simple to establish, and the model establishment time is short. Through ovarian pathological observation, it can be seen that the simulated animal model has obvious ovary tissue damage, follicular granulosa cell destruction and apoptosis, and follicle atresia and other symptoms. The obtained model has good stability and repeatability. The phytostilbene is used to successfully establish the early ovarian failure rat model, lays a good foundation for establishing a stable early ovarian failure model for basic research, and provides a reliable method for the construction of the early ovarian failure model.

The invention is suitable for the technical field of camellia oil application, and provides application of camellia oil in prevention and treatment of ovarian function decline. The invention reveals that the camellia oil has good prevention and improvement effects on the ovarian function decline for the first time. A series of rigorous scientific experiments prove that the camellia oil can effectively improve weight loss and reproductive hormone disorder caused by mouse ovarian function decline induced by cyclophosphamide, repair ovarian tissue damage and inhibit ovarian granular cell apoptosis, so that normal development of ovaries is promoted, the ovarian index is increased, and the effect of preventing and treating ovarian diseases is achieved. The number of atresia follicles is reduced, the pregnancy rate and the litter size are increased, and the occurrence of ovarian function decline is effectively prevented and improved. The discovery provides a scientific basis for preventing and improving ovarian function decline by using the camellia oil, and avoids tissue hyperplasia and canceration risks caused by strong stimulation of an endocrine system, reproductive organs and mammary gland by exogenous hormones in a hormone therapy.

The invention provides an ictalurus punctatus dnmt1 gene knockout RNAi target sequence, a sex regulation and control method and application, and belongs to the technical field of sex regulation and control. An RNAi sequence is designed based on the dnmt1 gene, and gonad differentiation intervention independent of exogenous hormones is realized in the species by inhibiting expression of the dnmt1 gene in the channel catfish. Experimental results show that dnmt1 expression down-regulation can effectively induce partial sex reversal of genetic female individuals, typical testis-like structures appear in ovarian tissues of the female individuals, it is proved that dnmt1 plays a key role in maintaining female gonad development stability, and it is hopeful that dnmt1 regulation is combined with a genetic screening or gene editing technology, so that the development stability of the female gonad is improved. A stable and efficient all-male channel catfish breeding system is established, and a new path is developed for all-male offspring seed production.

This invention belongs to the field of biomedical technology, specifically relating to the application of a composition in the preparation of a drug for the prevention and treatment of polycystic ovary syndrome (PCOS). The composition comprises bovine spleen peptide and adenosine; the mass ratio of bovine spleen peptide to adenosine is 1:(1-2.5). Bovine spleen peptide, as a bioactive polypeptide, significantly improves insulin resistance associated with PCOS by targeting and activating the PI3K-Akt signaling pathway and promoting insulin receptor substrate phosphorylation. Adenosine, as a natural bioactive substance, significantly reduces serum luteinizing hormone and testosterone levels in rats and increases follicle-stimulating hormone levels, thereby effectively alleviating hyperandrogenism symptoms such as hirsutism and acne in PCOS. Furthermore, this composition can significantly improve polycystic pathological changes in the ovarian tissue of model rats, reduce the number of cystic dilated follicles, restore the granulosa cell layer structure, alleviate ovarian stromal hyperplasia, and promote normal follicular development.

The embodiments of the present invention relate to the field of microorganisms, and in particular to a bacterial agent, a composition and an application thereof for preventing or improving polycystic ovary syndrome. The active ingredient of the bacterial agent includes plant lactobacillus (Lactiplantibacillus plantarum) G3, and the deposit number is CGMCC NO.27252. The plant lactobacillus G3 of the present invention, alone or in combination with thermophilic streptococcus and bulgaric lactobacillus delbrueckii, can correct irregular estrous cycles, improve ovarian polycystic lesions, sex hormone disorders and blood lipids, abnormal blood sugar metabolism, and by increasing the mRNA expression of oxidative stress-related factors in the ovary, effectively reduce the oxidative stress damage of ovarian tissue, and can be used to prevent, alleviate or treat PCOS. The effect of plant lactobacillus G3 in combination with thermophilic streptococcus and bulgaric lactobacillus delbrueckii is more significant.

To provide a system and a method for applying preferable energy to ovarian tissue.SOLUTION: Described herein are methods and systems 100 for performing a procedure for ovarian rebalancing. The methods and systems may be used in the treatment of polycystic ovary syndrome (PCOS). The methods and systems may also be useful in the treatment of infertility associated with PCOS.SELECTED DRAWING: Figure 1A

The application relates to application of FOS / AP-1 inhibitors in preparation of drugs for improving vitrification freezing damage of ovary tissues. The application provides a new concept and intervention target for female fertility preservation based on ovary vitrification freezing, and has a good application prospect.

Methods and systems for performing a surgical procedure for ovarian rebalancing are described herein. The methods and systems can be used to treat polycystic ovary syndrome (PCOS). The systems and methods can also be used to treat infertility associated with PCOS.

The invention relates to a traditional Chinese medicine effective component screening method based on a chemical fingerprint spectrum and multi-omics combined analysis. The method comprises the following steps: preparing a semen cuscutae-fructus lycii medicine pair extract and establishing a UPLC-Q-TOF-MS / MS chemical fingerprint spectrum; detecting the levels of estradiol, luteinizing hormone, anti-mullerian hormone and follicle-stimulating hormone in the premature ovarian insufficiency animal model; screening characteristic components related to the drug effect through multivariate statistical analysis; performing transcriptome sequencing on the ovarian tissue, and combining GO / KEGG analysis to determine a key pathway; integrating database prediction targets and differential genes, screening hub genes and constructing a protein interaction network; and finally verifying the binding activity of the candidate component and the core target protein through molecular docking and molecular dynamics experiments. According to the invention, systematic screening and action mechanism analysis of drug effect related components are realized, and a new technical approach is provided for mass marker determination and estrogen simulating action research of the dodder-wolfberry drug pair.

The present invention discloses the application of the PLPP3 gene in regulating autophagy in human ovarian granulosa cells, belonging to the field of cell engineering and genetic engineering technology. The present invention discovered for the first time that overexpression of the PLPP3 gene can significantly increase the levels of autophagy and apoptosis in granulosa cells; while interfering with the expression of the PLPP3 gene significantly reduces the levels of autophagy, apoptosis and cell activity in granulosa cells. It was also found that the PLPP3 protein level was low in the ovarian tissue of middle-aged people; while the PLPP3 protein level was high in the ovarian tissue of the elderly. The PLPP3 protein level was positively correlated with the degree of human ovarian aging and can be used as a marker to diagnose / evaluate the level of human ovarian aging. The present invention has great application value in studying the mechanism of the influence of autophagy regulation on ovarian follicle development, reproductive capacity and ovarian-related diseases, and has important clinical value in protecting ovarian function and treating ovarian-related diseases.

The invention discloses an ovarian tissue low-temperature cryopreservation solution as well as a preparation method and application thereof, and relates to the technical field of biomedical materials. The invention relates to an ovarian tissue low-temperature cryopreservation solution as well as a preparation method and application thereof. Every 100 ml of the ovarian tissue low-temperature cryopreservation solution comprises 15-25 ml of dimethyl sulfoxide, 15-25 ml of ethylene glycol, 15-20 g of polysucrose, 38-46 g of sucrose, 40-45 ml of a phosphate buffer solution and 0.12-0.13 g of human serum albumin. According to the low-temperature cryopreservation solution for the ovarian tissues, the dimethyl sulfoxide and the ethylene glycol are used as permeable low-temperature protective agents to prevent the ovarian tissues from being damaged at low temperature, and the polysucrose and the sucrose are used for regulating the cell osmotic pressure to improve the cell dehydration effect, reduce the formation of ice crystals in cells and increase the viscosity of the solution; according to the low-temperature cryopreservation solution for the ovarian tissue, the solution forms an amorphous glassy state instead of ice crystals in the freezing process, the human serum albumin maintains osmotic pressure and nutrition, the tissue survival rate and the functional integrity are guaranteed, the ovarian tissue can be efficiently cryopreserved through the low-temperature cryopreservation solution for the ovarian tissue, and the follicle survival rate and the functional integrity after ovarian transplantation are effectively improved.

The application provides application of a hydrogen sulfide donor SPRC in improving early-onset ovarian dysfunction caused by a chemotherapy drug, and relates to the technical field of biomedicine, and the technical key points are as follows: the application provides application of the hydrogen sulfide donor SPRC in preparing a drug for improving early-onset ovarian dysfunction. The present application aims at the technical problems of early-onset ovarian dysfunction causing the decline of female ovarian function and reproductive capacity, including the decline of ovarian index, the reduction of the number of follicles at all levels, and the significant increase of the number of apoptotic cells in ovarian tissue. The specific verification experiments prove that supplementing the hydrogen sulfide donor SPRC in a mouse model of early-onset ovarian dysfunction can improve the body weight and ovarian index of the mouse, and maintain the normal morphology of the ovary. Specifically, the SPRC can improve the number and quality of follicles in the ovary by reducing cell apoptosis, and ultimately rescue the ovarian damage caused by POI.

The invention provides an application of a hydrogen sulfide donor SPRC in improving early-onset ovarian insufficiency caused by chemotherapeutic drugs, relates to the technical field of biomedicine, and has the technical key point that the application of the hydrogen sulfide donor SPRC in preparing drugs for improving the early-onset ovarian insufficiency is provided. The application aims to solve the technical problems that the ovarian function and reproductive capacity of women are reduced, including the ovarian index is reduced, the number of follicles at all levels is reduced and the number of apoptotic cells in ovarian tissues is remarkably increased, caused by premature ovarian insufficiency at present. Specific verification experiments prove that by supplementing a hydrogen sulfide donor SPRC in a premature ovarian insufficiency mouse model, the weight and the ovarian index of the mouse can be increased, the normal form of the ovarian can be maintained, specifically, the SPRC can improve the number and the quality of follicles in the ovarian by reducing cell apoptosis, and finally ovarian injury caused by POI is rescued.

The invention belongs to the field of bioelectromagnetism, and particularly discloses a method for improving functions of frozen and thawed ovarian tissues by adopting an mT-level pulsed magnetic field. According to the method, ovarian tissue which is subjected to vitrification freezing and resuscitation is exposed in a pulsed magnetic field with specific parameters for intervention treatment; wherein the intensity of the pulsed magnetic field is 5 mT, the current period is 1000-6000 [mu] s, the duty ratio is 50%, the pulse repetition number is 30, and the pulse interval is 60 ms. According to the application, a non-intrusive and drug-residue-free physical intervention means is adopted, inflammatory response can be effectively inhibited, oxidative stress injury can be relieved, the number of functional mitochondria is increased by up-regulating mitochondrial fusion genes (such as Mfn1 and Mfn2), the energy metabolism state of cells is fundamentally improved, the survival rate of transplanted ovarian tissue is remarkably increased, the functional life of the ovarian tissue is prolonged, and the survival rate of the ovarian tissue is increased. The method is simple to operate, low in cost and good in clinical application prospect.

This invention discloses the application of a DMSO-free cryopreservation solution in the cryopreservation of organs and / or tissues. The cryopreservation solution, per 100 mL volume, contains 0.01-50.0 g of a biomimetic ice-controlling material, 5.0-30 mL of polyol, 1-30 g of water-soluble sugar, 0-30 mL of serum, with the remainder being buffer solution. The biomimetic ice-controlling material is selected from PVA and / or amino acid-based biomimetic ice-controlling materials. The cryopreservation solution and cryoequilibration solution of this invention do not contain DMSO, exhibiting high preservation efficiency when used for cryopreservation of ovarian tissue or organs. Furthermore, the DMSO- and serum-free cryopreservation solution further solves the problems of poor stability and the potential introduction of parasitic biological contaminants caused by the presence of serum in currently widely used commercial cryopreservation solutions. The cryopreservation solution of this invention has a simple composition, readily available raw materials, and low cost, and can be widely used for the cryopreservation of various organs or tissues.

The invention discloses a preparation method and application of a Muscovy duck MAPK1 protein polyclonal antibody, and belongs to the technical field of biology. According to the invention, DNAStar software, AI-assisted protein three-dimensional structure prediction and other bioinformatics methods are adopted to accurately determine the 4th-364th amino acids of MAPK1 as immunogens, and protein expression, purification and antibody preparation methods are optimized to obtain the preparation method: expressing an MAPK1 recombinant protein with an amino acid sequence of SEQ ID NO.2, and immunizing a rabbit with the recombinant protein to obtain the Muscovy duck MAPK1 protein polyclonal antibody. The titer of the obtained polyclonal antibody can reach 1: 102400, and the polyclonal antibody has the advantages of high recognition efficiency and strong specificity. The MAPK1 polyclonal antibody prepared in the invention has high targeting recognition capability at the tissue level, can be used for immunofluorescence visualization research of Muscovy duck ovarian tissue protein expression, and provides key technical support for subsequent function exploration of MAPK1 in follicular development and reproduction regulation.